

Market Round-up

Proudly sponsored by:

FRESH
PERSPECTIVES

V20 – 5th October 2018

General Market News:

- **GSK** is overturning a blanket ban on payments to doctors promoting its medicines, now allowing the practice under certain circumstances.
[LINK](#)
- Draft guidelines from NICE do not recommend NHS funding for **Takeda's** lung cancer drug **Alunbrig**.
[LINK](#)
- NHS England has agreed to provide funding for **Janssen's Symtuza**, a once-daily darunavir-based single tablet regimen (STR) for the treatment of HIV in adults and adolescents. This decision allows clinicians across England to routinely prescribe Symtuza on the NHS for eligible patients.
[LINK](#)
- **Novartis'** generics arm **Sandoz** has launched the second Healthcare Access Challenge, which is looking to support digital solutions to local healthcare access challenges.
[LINK](#)
- **Novartis** are seeking to cut the company's workforce from 124,000 to under 100,000 by 2022 as the company grapples with major marketing and manufacturing issues.
[LINK](#)
- **GSK** is to change its direct-to-pharmacy medicines distribution model to a reduced wholesaler system from next month.
[LINK](#)
- **Boston Pharmaceuticals** confirmed it has reached separate deals with both **Novartis** and **GSK**, licensing a total of eight drug candidates.
[LINK](#)
- **Roche's Hemlibra**, on sale since late 2017 for patients with resistance to existing treatments, is widely expected to win FDA approval this week.
[LINK](#)
- **MSD** runs out of Parkinson's disease drug **Sinemet** as manufacturing issues, forecasting miss lead to shortage.
[LINK](#)
- **MSD's** HIV drug **Delstrigo** shows long-term treatment effect in late-stage switching study.
[LINK](#)
- **GSK** has reported positive results from the Phase IV Harmony Outcomes trial evaluating the effect of **albiglutide** on major adverse cardiovascular events.
[LINK](#)

NCPE Drug Updates

- No updates this week.

Drug Approvals:

- **Sanofi** and **Regeneron's** immunotherapy **Libtayo** has been cleared in the US to treat patients with certain forms of cutaneous squamous cell carcinoma (CSCC).
[LINK](#)
- **Eli Lilly's** breast cancer drug **Verzenio** has been approved in Europe for the treatment of certain breast cancers
[LINK](#)
- **Eli Lilly's** migraine drug **galcanezumab (Emgality)** has received FDA approval. This is the third in new class of medicines behind **Teva** and **Amgen**
[LINK](#)
- The FDA has approved single-dose prefilled syringes of **Xolair** from **Roche** and **Novartis**.
[LINK](#)
- NICE is recommending the inclusion of **Pfizer's XELJANZ** (tofacitinib) for treating patients with active psoriatic arthritis
[LINK](#)
- **Amgen** announced that the FDA has approved its supplemental new drug application for its multiple myeloma drug, **Kyprolis** (carfilzomib), in combination with **dexamethasone** (Kd).
[LINK](#)

Drug Approval Submissions:

- **Astellas** files for **Roxadustat** approval in Japan
[LINK](#)

Brexit:

- Six months to go until Brexit: All you need to know
[LINK](#)
- Medical research group **Recardio** has reportedly halted a trial of an experimental heart drug because of uncertainties surrounding the UK's departure from the European Union.
[LINK](#)

Further Reading:

- Who is Albert Bourla, the next **Pfizer** CEO?
[LINK](#)
- Call for fresh approach to funding new medicines (*Irish Times Article*)
[LINK](#)
